 MD News (press release) | Everolimus Ups Survival in Carcinoid Syndrome MD News (press release) For patients with low- or intermediate-grade advanced neuroendocrine tumors (carcinoids), everolimus plus octreotide long-acting repeatable (LAR) improves progression-free survival versus placebo plus octreotide LAR, according to a study published ... |
